Our emails have transitioned to the Revvity.com domain, however our billing information is unchanged. Click for details.

Transfection and Transduction Reagents

Versatile tools for effective transfection and transduction with minimal cellular toxicity

The success of any gene modulation experiment, whether RNAi knockdown, CRISPR editing, or lentiviral cell engineering, depends on one critical step: efficient, low-toxicity delivery of your RNA or DNA cargo into target cells.

Our DharmaFECT™ family of lipid-based transfection reagents is purpose-built for:

  • High-efficiency delivery across diverse cell types 
  • Low cellular toxicity to preserve experimental integrity
  • Broad dynamic range for flexible experimental design

For lentiviral applications, LentiBOOST™ transduction enhancer elevates delivery success in hard-to-transduce cells and complex cell engineering workflows, while minimizing viral particle requirements and maintaining cell viability. LentiBOOST technology is actively used in the production of clinical-stage lentiviral-delivered therapies, offering a direct path from research to therapeutic applicability.

The Trans-lentiviral packaging systems are available for efficient generation of replication-incompetent lentiviral particles to deliver shRNA or ORF constructs in dividing and non-dividing mammalian cells. 

transfection and transduction reagent bottles and vials 

Select the appropriate DharmaFECT formulation for the delivery of small RNAs

  • The table below lists transfection recommendations to help you select the appropriate DharmaFECT formulation for your research.

    You can also download a PDF version of the DharmaFECT Cell Type Guide.

    Human
    Cell line Cell type Recommended DharmaFECT formulation DharmaFECT volume/well (μl) in 96 well plate Plating density in 96 well plate (cells per well) Other successful formulations
    786-0 Kidney adenocarcinoma 1 0.4 5 × 103 2
    A549 Lung carcinoma

    1

    0.2

    1 × 104

    2, 3, 4

    BxPC3

    Pancreas adenocarcinoma

    2

    0.2

    5 × 103

    1, 3, 4

    DLD-1

    Colorectal adenocarcinoma

    2

    0.4

    5 × 103

    1,3

    DU 145

    Prostate carcinoma

    1

    0.2

    1 × 104

    2, 3, 4

    NCI-h2299

    Lung carcinoma

    2

    0.2

    1 × 104

    4

    HCT-116

    Colorectal carcinoma

    2

    0.1

    5 × 103

    4

    HEK293

    Kidney transformed embryonic cells

    1

    0.2

    1 × 104

    2, 4

    HeLa

    Cervical epithelial adenocarcinoma

    1

    0.2

    5 × 103

    2, 3, 4

    HeLa S3

    Cervical epithelial adenocarcinoma

    4

    0.4

    5 × 103

    1, 2, 3

    Hep G2

    Hepatocellular carcinoma

    4

    0.4

    1 × 104

    1, 2

    hMSC

    Mesenchymal stem cells

    1

    0.4

    5 × 103

    2, 3, 4

    HT-29

    Colorectal carcinoma

    1

    0.2

    5 × 103

    2, 3, 4

    HT1080

    Fibrosarcoma

    4

    0.2

    5 × 103

    1, 2, 3

    Huh-7

    Hepatocarcinoma

    4

    0.05

    5 × 103

    1, 2

    HUVEC

    Umbilical vein endothelial cells

    4

    0.2

    2 × 104

    1, 2

    LNCaP

    Prostate carcinoma

    3

    0.2

    1 × 104

    1

    MCF-10a

    Breast adenocarcinoma

    1

    0.2

    1 × 104

    2

    MCF-7

    Breast adenocarcinoma

    1

    0.2

    1 × 104

    2, 4

    MDA-MB-453

    Breast adenocarcinoma

    2

    0.2

    1 × 104

    1, 3, 4

    MDA-MB-231

    Breast adenocarcinoma

    4

    0.1

    5 × 103

    1

    OVCAR-3

    Ovarian adenocarcinoma

    1

    0.1

    5 × 103

    2, 3, 4

    PC-3

    Prostate carcinoma

    2

    0.2

    1 × 104

    3

    SK-BR3

    Breast adenocarcinoma

    2

    0.2

    1 × 104

    1, 3, 4

    SK-OV-3

    Ovarian adenocarcinoma

    3

    0.4

    1 × 104

    1, 2, 4

    u87MG

    Brain glioblastoma

    1

    0.1

    5 × 103

    2, 3, 4

    Rodent
    Cell line Cell type Recommended DharmaFECT formulation DharmaFECT volume/well (μl) in 96 well plate Plating density in 96 well plate (cells per well) Other successful formulations

    A7r5

    Rat aortic smooth muscle

    2

    0.1

    5 × 103

    1

    C2C12

    Mouse myoblasts

    1

    0.2

    5 × 103

    2, 3, 4

    CHO K1

    Chinese hamster ovary cells

    4

    0.8

    1 × 104

    1, 2

    ES-D3

    Mouse embryonic stem cells

    1

    0.2

    2 × 103

    2

    ES-E14TG2a

    Mouse embryonic stem cells

    1

    0.2

    2 × 103

    2

    H9c2

    Rat myoblasts

    1

    0.2

    1 × 104

    2, 3, 4

    J774A.1

    Mouse macrophages

    4

    0.2

    1 × 104

    -

    NIH/3T3

    Mouse embryonic fibroblasts

    1

    0.2

    1 × 104

    3

    NRK-49F

    Rat kidney fibroblasts

    2

    0.2

    1 × 104

    1, 4

    Rat2

    Rat fibroblasts

    1

    0.2

    2 × 104

    2

    3T3-L1

    Mouse embryonic fibroblasts

    1

    0.2

    5 × 103

    3

    Other
    Cell line Cell type Recommended DharmaFECT DharmaFECT μl/well Plating density (cells/well) Other successful formulations

    COS-7

    African green monkey kidney

    2

    0.4

    5 × 103

    1, 3, 4

    All experimental conditions resulted in cell viability and positive control gene silencing of 80% or better. All experiments were done in 96-well plates with non-targeting control siRNA and PPIB (Cyclophilin B) or GAPD Control pools at 25 nM; Alamar Blue (viability) and knockdown measured at 24 hours. Data normalized to untransfected for viability and both untransfected and non-targeting control for knockdown. Transfection conditions should always be re-evaluated in the context of a new plate format or assay-specific requirements for cell density.

Inquire for special pricing on large volumes

We are here to answer your questions.

Contact us